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Acute myeloid leukemia (AML), the most comamon form of acute leukemia in adults, is a hetaerogeneous group of diseases that currently are 
curable in about 30 percent of cases.1 Advances to ima
prove the longastatic treatment outcome in AML are ura
gently needed. Traditionally, AML is grouped into three 
prognostically relevant categories2 based on cytogenetic 
analyses: First, the balanced translocations, which are asa
sociated with a favorable prognosis, including t(15;17), 
t(8;21) and t(16;16) or inv(16)(p13;q32). Second, a 
complex aberrant karyotype that confers a poor clinical 
outcome. And third, an intermediate prognosis group, 
including normal karyotype and other karyotypic aba
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cytogenetic aberrations have long been recognized as the most important prognostic variable in acute 
myeloid leukemia (aml) and are now a major stratification tool for post-remission therapy. cytogenetics-
based stratification improves survival. patients with aml and normal cytogenetics, the largest single 
subgroup, have had a very heterogeneous outcome with standard chemotherapy in multiple clinical 
trials. hence it is difficult to recommend a “one size fits all” kind of treatment for this heterogeneous 
population of aml patients. new emerging data from preclinical, retrospective, and large, randomized 
controlled studies indicate that in addition to cytogenetic abnormalities, many other molecular aberra-
tions are operative in the response to treatment as well as in the risk of relapse. such molecular markers 
are being tested for developing targeted therapies and may help in improved stratification of patients 
in the selection of post-remission therapy. emerging evidence reveals that at the submicroscopic level, 
aml with normal cytogenetics may carry poor prognostic genetic lesions or “molecular signatures” as 
is the case with FLT3 mutations and overexpression of BAALC, ERG or MN1, or may have aberrations 
that predict better risk as is the case with isolated NPM1 or CEBPA mutations. later studies have tried to 
explore the interaction of various prognostically important genes in this group of aml patients. the util-
ity of the evolving data for bedside management of such patients is expected to improve with the wider 
application of modern tools, using the proposed clinical outcome models, and probably by development 
of a risk-scoring system based on the relative risk associated with each molecular aberration. the goals 
include identifying those patients most likely to benefit from upfront allogeneic hsct and sparing good-
prognosis patients from unnecessary transplant-related morbidity. the following is an outline of the most 
common molecular changes, their impact on the outcome of aml patients with normal cytogenetics and 
challenges in their wide scale application in risk stratification. 
normalities that do not fall into a gooda or poorarisk 
karyotype, e.g., t(9;11)(p22;q23). Patients with a nora
mal karyotype comprise the single largest cytogenetic 
subset in AML as no chromosomal abnormality is visia
ble by conventional karyotyping in 40% to 50% of adult 
cases and in 25% of pediatric cases. Normal karyotype 
is associated with 5ayear survival rates between 24% 
and 42%, and biologic features of this large cytogenetic 
subgroup are still poorly understood.2,3 Hence most of 
these cases are presently classified in the World Health 
Organization (WHO) scheme4 under the term “acute 
myeloid leukemia not otherwise characterized”. Based 
on recent findings, discussed below in detail, this clasa
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sification is under revision and is expected to incorpoa
rate more molecular genetics (personal communication. 
Clara D Bloomfield MD).
Recent data have shown that this cytogenetic suba
group is genetically heterogeneous.1,3 A number of 
submicroscopic genetic lesions with prognostic impact 
have been identified in patients with AML and a nora
mal karyotype. Such genetic lesions provide some hints 
towards understanding the biology of this subset of 
AML patients and hence may provide new approaches 
for subaclassification of AML with a normal karyotype. 
More than 100 genes have been reported to be altered 
in their physiological function by rearrangements, mua
tations, underexpression or overexpression, and some 
of these can serve as markers for prognosis, detection 
of minimal residual disease (MRD) and for the devela
opment of targeted therapies for AML patients. These 
mutations in AML may be divided into two broad 
categories: mutations that activate signal transduction 
cascades and mutations in genes that result in dysregua
lated gene transcription. This article is not intended to 
provide a comprehensive review of all potentially ala
tered genes, but will focus on the most frequently and 
most recently recognized dysregulated genes in AML 
with normal cytogenetics (Figure 1). These include nua
cleophosmin 1 (NPM1), FMSalike tyrosine 3 (FLT3), 
CCAAT/enhancerabinding protein α (CEBPA), partial 
tandem duplication (PTD) of the mixed lineage/mya
eloid lymphoid leukemia (MLL) gene, brain and acute 
leukemia cytoplasmic (BAALC) gene, ETSarelated 
genes (ERG), neuroblastoma RAS viral oncogene hoa
molog gene (NRAS), meningioma 1 (MN1) gene and 
Wilm’s tumor 1 (WT1) gene (Table 1); and the role 
of microarray gene expression profiling in constructing 
an optimal clinicalaoutcome prediction model that may 
prove more accurate in predicting survival among AML 
patients with a normal karyotype.
We also describe how these molecular findings can 
be utilized in stratifying patients for riskaadapted and 
targeted treatments, including a description of clinical 
outcome models proposed in recent studies that may 
help hematologists in identifying patients most likely 
to benefit from upfront allogeneic hematopoietic stem 
cell transplantation (HSCT) and spare goodaprognosis 
patients from unnecessary transplantarelated morbidity 
and or mortality. Finally we propose that, with the aca
cumulation of information about the relative impact of 
each aberration on clinical outcome, there is a need to 
develop a scoring system incorporating all (or selected) 
molecular markers for prospective decision making.
Mutations in the nucleophosmin 1 (NPM1) gene
The nucleophosmin (NPM1) gene encodes for a multia
functional nucleocytoplasmic shuttling protein that is 
localized mainly in the nucleolus. NPM1 mutations 
generate NPM mutants that localize aberrantly in the 
leukemicacell cytoplasm.5,6 Both tumorasuppressor and 
oncogenic functions have been attributed to this mula
tifunctional phosphoprotein. NPM promotes the bioa
genesis of the ribosome by acting as a chaperone that 
carries preribosomal particles from the nucleolus to the 
cytoplasm and by favoring the processing and matua
ration of ribosomal RNA.7 This may prevent protein 
aggregation in the nucleolus.6,8 NPM has been implia
cated in modulation of the function of tumorasuppresa
sor transcription factors, such as interferon regulatory 
factor 1 (IRFa1) and the regulation of the alternatea
readingaframe protein (ARF)ap53 tumorasuppressor 
pathway9a12 and is also a target of CDK2acyclin E coma
plexes in centrosome duplication.13 As NPM controls 
the p19ARFap53 tumor suppressor pathway at multiple 
levels,9 this may suggest a tumorasuppressor role for 
NPM itself. However, NPM, when overproduced, can 
transform immortalized cells and is highly expressed in 
various tumors and in actively proliferating cells, again 
suggesting its role in ribosome biogenesis.
The complex physiological functions of NPM ina
clude regulation of DNA integrity and inhibition of 
cell proliferation by interaction with p19ARF.9 Animal 
models have established that NPM is essential for ema
bryonic development and the maintenance of genomic 
NPM1
CEBPA
FLT3-ITD
FLT3-TKD point mutation
MLL-PTD
BAALC overexpression
ERG overexpression
MN1 overexpression
NRAS mutation
WT1 mutations
Figure 1. Reported frequencies (%) of some genetic alterations in AML patients with 
normal karyotypes. Smaller values reported in selected references are shown as 
unshaded portions. 
NPM1: nucleophosmin 1; FLT3-ITD: FMS-like tyrosine kinase 3–internal tandem duplication; FLT3-TKD: 
FMS-like tyrosine kinase 3-tyrosine kinase domain; CEBPA: CCAAT/enhancer binding protein alpha; MLL-
PTD: partial tandem duplication of the mixed lineage leukemia/myeloid lymphoid leukemia; BAALC: brain and 
acute leukemia cytoplasmic gene; ERG: ETS-related genes; MN1: meningioma 1; NRAS: meuroblastoma rat 
sarcoma gene, WT1: Wilms tumor 1 antigen. 
Frequency (%)
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stability.14 Moreover, NPM haploainsufficiency accelera
ates oncogenesis in in vitro and in vivo model systems. 
Mice expressing a hypomorphic NPM allele develop a 
hematological syndrome similar to human myelodysa
plastic syndrome (MDS), which points to a central role 
for NPM in the pathogenesis of AML. 
Chromosomal translocations involving the NPM1 
gene frequently occur in myeloid and lymphoid cancers 
and result in fusion proteins containing only the NPM 
Naterminal region.15,16 Such fusions include NPMaanaa
plastic lymphoma kinase (NPMaALK),17 NPMaretinoic 
acid receptor α (NPMaRARα),18 and NPMamyeloid 
leukemia factor 1 (NPMaMLF1).19 Rearrangements 
with the MLF1 gene occur in AML, chronic myeloga
enous leukemia, and myelodysplasia.17a19 NPM appears 
to contribute to oncogenesis by activating the oncogenic 
potential of the fused protein partner (MLF1, ALK or 
RARα). As NPM is thought to have a tumorasuppressor 
function, abnormalities leading to its movement from the 
nucleus to the cytoplasm may be critical for malignant 
transformation. Such changes in the subcellular distribua
tion of NPM and NPMacontaining fusion protein can 
be detected by immunohistochemical methods.16,18 
Cytoplasmic NPM accumulation is caused by the 
concerted action of two alterations at a mutant Catera
minus, that is, changes of tryptophan(s) 288 and 290 
(or only 290) and creation of an additional nuclear 
export signal (NES) motif.15 According to recent studa
ies NPM1 exona12 gene mutations represent the most 
common submicrosopic alterations in patients with 
a normal karyotype (occuring in 50% to 60% of adult 
acute myeloid leukemia patients) and have a profound 
diagnostic and prognostic impact.3,14,15,20 Recently, Falini 
et al identified a large subgroup of patients with AML 
who had cytoplasmic NPM in leukemic blasts, a mua
tated NPM gene, a normal karyotype, and a relatively 
good response to induction chemotherapy.3 They have 
shown that an abnormal cytoplasmic localization of the 
NPMaprotein (NPMc+) can be found in about 35% of 
all patients with primary AML, but not in secondary 
AML and other hematopoietic or extraahematopoietic 
neoplasms other than AML.3 In this study, NPMc+ 
did not occur with specific recurrent chromosomal aba
normalities. Cytoplasmic NPM staining was associated 
with responsiveness to induction chemotherapy.3 The 
frequency pattern of NPMc+ ranged from 13.6% in 
M0 tumors (minimally differentiated AML) to 87.5% 
in M5b specimens (acute monocytic leukemia). Most 
NPMc+ AML tumors of the M5b and M6 subtypes 
(acute erythroid leukemia) showed cytoplasmic NPM 
Table 1. Prognostic impact of dysregulated gene(s) described in AML patients with normal karyotype.
Genetic 
alterations 
Gene 
location
Reported frequency in AML 
patients with normal karyotype Impact on clinical outcome
NPM1 
mutations 5q35 49.6%,
133 60%,3§ 53%131 Favorable especially in absence of FLT3-ITD; better CR, EFS, RFS, DFS, and OS
CEBPA 
mutations 19q13.1 7-15%
99,100,131,133 Favorable; higher CR duration and OS 
FLT3-ITD 13q12 17-31%44,45,131
Unfavorable especially if coupled with no expression of a 
FLT3 wild-type allele or a high FLT3 mutant to FLT3 wild-type 
allele ratio; shorter CR duration, DFS and OS
FLT3-TKD point 
mutations 13q12 5-14%
20,45,131,133 None but may be favorable if associated with NPM1 mutation 
MLL-PTD 11q23 7-11%44,76,79,82,131,133 Unfavorable; shorter CR duration 
BAALC 
overexpression 8q22.3 19%,
83  50%44,46,86 Unfavorable; lower CR rates and shorter DFS and OS
ERG 
overexpression 21q22.3 25%,
44**  37%96 Unfavorable; lower CR rates, higher relapse and shorter OS
MN1 
overexpression 22 q11 50%
107,138 Unfavorable; shorter relapse-free survival, ATRA resistance 
in elderly
NRAS mutation 1p13 9.1-13%110,131 None but may be favorable OS when other gene aberrations are taken into account
WT1 mutation 11p13 10%124 Unfavorable; associated with induction failure
§Cytoplasmic NPM staining3 ; **Based on quartile expressing the highest ERG level in a group of 84 patients; OS: overall survival; DFS: disease free survival; CR: complete 
remission; ATRA: all-trans retonoic acid; NPM1: nucleophosmin 1; FLT3-ITD: FMS-like tyrosine kinase 3–internal tandem duplication; FLT3-TKD: FMS-like tyrosine kinase 3-tyrosine 
kinase domain; CEBPA: CCAAT/enhancer binding protein alpha; MLL-PTD: partial tandem duplication of the mixed lineage leukemia/myeloid lymphoid leukemia; BAALC: brain and 
acute leukemia cytoplasmic gene; ERG: ETS-related genes; MN1: meningioma 1; NRAS: meuroblastoma rat sarcoma gene, WT1: Wilms tumor 1 antigen. 
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in erythroid precursors, particularly proerythroblasts.3 
However, NPM abnormalities may not be the only 
molecular event in myeloid leukemic blasts; there was 
a high frequency of FLT3 internal tandem duplications 
and an absence of CD34 and CD133 in AML specia
mens with a normal karyotype and cytoplasmic dislocaa
tion of NPM, but not in those in which the protein was 
restricted to the nucleus (P<.001).3 
Many other European leukemia groups have provided 
an extensive analysis of NPM1 and FLT3 mutations, 
as well as other mutations with prognostic significance 
in AML.20a25 Earlier, in a cancer and leukemia group B 
(CALGB) study, Whitman et al showed that absence of 
the wildatype allele predicts poor prognosis in adult de 
novo AML with normal cytogenetics and the internal tana
dem duplication of FLT3 (FLT3-ITD).25 According to the 
study by Schnittger et al, comprising of 401 patients with 
a normal karyotype FLT3-ITD mutations were found in 
40% of patients with NPM1 mutations and represented 
the most frequent additional genetic alteration in patients 
with a mutated NPM gene.20 Interestingly, the favorable 
impact of NPM1 mutations on achieving higher coma
plete remission (CR) rate and eventafree survival (EFS) 
was clearly seen in the group of normalakaryotype AML 
without FLT3 length mutations (FLT3-LM). This favora
able effect was lost in the presence of a FLT3-ITD since 
survival of the NPM1+/FLT3-LM+ double positive was 
similar to NPM1a/FLT3-LM+ cases.20 Hence this study 
demonstrated that NPM1+/FLT3-LMa mutations are 
an independent predictor for a favorable outcome in 
AML with normal karyotype.20
With limitations of significant differences in mea
dian time of followaup, median age, maleafemale ratio, 
treatment regimens, and possibly outcome; the esa
sential conclusions related to NPM1 mutations were 
concordant in all European reports.20a23 Of most ima
portance, isolated NPM1 mutations were found to 
predict for improved OS,20a22 relapseafree survival,20,21 
and eventafree survival (EFS)20,22 in AML with normal 
karyotype by KaplanaMeier analysis only if FLT3-ITD 
mutations were not coincidentally present (i.e. in the 
NPM1+FLT3asubgroup). There were no survival difa
ferences between NPM1+FLT3+, NPM1aFLT3+, 
and NPM1aFLT3asubgroups. Other concordant cona
clusions were that NPM1 mutations are not related to 
age, occur more often in females, are associated with 
increased WBC count, are more frequently associated 
with the myelomonocytic phenotype and low CD34 
expression, and occur less frequently with coincident 
partial tandem duplication of MLL.20,21,23 Schnittger et 
al and Verhaak et al also reported an independent sura
vival advantage for NPM1 mutation alone by multivaria
ate analysis and a decreased coincidence of NPM1 and 
CEBPA mutations.20,22 Very recent data suggests that 
NPM1 mutations, which are frequently associated with 
FLT3 mutations, are more stable than FLT3 mutations 
during the course of disease in patients with AML. 
Hence these highly prevalent mutations of NPM1 
might provide a suitable marker for monitoring residual 
disease of AML.26
The prevalence of the NPM1 gene mutation in nona
M3 childhood AML patients with normal karyotype 
enrolled in an Italian study was 6.5% (in 107 successfula
ly analyzed patients).27 NPM1amutated patients were 
older in age.27 More recent pediatric data confirms that 
frame shift mutations in exon 12 of the nucleophosa
min gene are relatively uncommon (8%) in childhood 
AML, particularly in younger children.28 Both studies 
confirm that NPM mutation does not abrogate the 
negative prognostic influence of FLT3-ITD mutations, 
but may contribute to risk stratification in children who 
lack FLT3-ITD mutations by identifying a group with 
superior prognosis.28 
NPM1 mutations are associated with several prea
treatment characteristics of patients with AML and 
normal karyotype, including a predominance of female 
sex, wide morphologic spectrum, multilineage involvea
ment, higher white blood cell and bone marrow blast 
percentages, higher lactate dehydrogenase levels, as well 
as high CD33aantigen expression but low or absent 
CD34aantigen expression, high frequency of FLT3-
ITD, and a distinct geneaexpression profile.15 
In summary, at present NPM mutations represent 
the most common submicrosopic alterations in adult 
patients with a normal karyotype and have a profound 
diagnostic and prognostic impact in constructing an opa
timal clinicalaoutcome prediction model.3,14,20 Analysis 
of mutated NPM has important clinical and pathologic 
applications. Immunohistochemical detection of cytoa
plasmic NPM predicts NPM1 mutations and helps raa
tionalize cytogenetic/molecular studies in AML. Due 
to their frequency and stability, NPM1 mutations may 
become a new tool for monitoring MRD in AML with 
normal cytogenetics.15 
Obviously these data will have a major impact on 
molecular investigative and clinical approaches in AML 
with normal karyotype. For example, the higharisk proa
cedure of allogeneic stem cell transplantation may not 
be indicated in first CR for this newly defined, favora
ableaprognosis subgroup as it did not improve the longa
term 60% relapseafree survival rate in NPM1+FLT3a 
cases but, as reported by Dohner et al,21,23 it did so in 
the other subgroups. On the other hand, it is potentially 
possible that treatment with recently developed FLT3 
reviewRISK STRATIFICATION IN AML WITH NORMAL KARYOTYPE
Hematol Oncol Stem Cell Ther 1(3)     July 2008 hemoncstem.edmgr.com 145
inhibitors25,29a33 might be effective in NPM1+FLT3+ 
patients by producing pharmacologic conversion to a 
more chemotherapyasensitive NPM1+FLT3a status.23 
A recent in vitro study suggested that abrogation of 
the levels or reversing the aberrant cytosolic localization 
of mNPM1 may be a promising antialeukemia treata
ment strategy, especially for targeting AML that coaexa
press FLT3-ITD and mutant NPM1.34
Mutations of the FMS-like tyrosine 3 (FLT3) gene
FLT3 (FMSalike tyrosine kinase) is a transmembrane 
tyrosine kinase, belonging to class III of receptor tyroa
sine kinases (RTK), in which ligand binding triggers a 
proaproliferative signaling cascade. The FLT3 gene bea
longs to the same family as FMS, KIT and the two genes 
encoding PDGFR α and β. A mutation of FLT3, is the 
most common tyrosine kinase mutation in AML.35 At 
mRNA level, it is expressed in 80%a100% of blasts from 
patients with AML,36 while combined data from mula
tiple studies shows 66% positivity by flowcytometry in 
AML cases.36 FLT3 is expressed at high levels in 50% of 
such patients with AML.37 Kuchenbauer et al showed 
that FLT3 expression levels were different in certain 
FAB types with a minimum in FAB M3 and maximum 
in FAB M5. Their results also correlated with the FLT3 
receptor surface expression (CD135) detected by flow 
cytometry (P<.001), showing the highest CD135 exa
pression in FAB M5.38 
Approximately 30% of the AML patients have actia
vating mutations in FLT3. The most frequent (~25%) 
is an internal tandem duplication (ITD) within the cya
toplasmic juxtamembrane ( JM) region. Less frequent 
(~7%) are point mutations in the activation loop of 
the tyrosine kinase domain (FLT3-TKD mutation), 
such as the D835Y mutation.37 Both types of mutaa
tions result in ligandaindependent kinase activation 
of FLT3 and its downstream signaling pathways such 
as signal transducer and activator of transcription 5 
(STAT5), RAS/mitogenaactivated protein kinase 
(RAS/MAPK), phosphoinositide 3akinase (PI3K), 
src homologous and collagen gene (SHC), SH2acona
taining inositola5aphosphatase (SHIP), and cytoa
plasmic tyrosine phosphatase with 2 Srcahomology 
2 (SH2) domains (SHP2), providing the cells with a 
proliferative and survival advantage.37,39 
According to the Gilliland model,37 type I mutaa
tions represent genetic alterations which induce a 
proproliferative and antiaapoptotic signal (e.g. gain of 
function mutations of protein tyrosine kinase [PTK] 
and ras), whereas type II mutations interfere with difa
ferentiation and often involve myeloid transcription 
factors (loss of function mutations). This model is supa
ported by experimental data indicating that AML1a
ETO and FLT3-ITD mutations are both insufficient 
on their own to cause leukemia in animal models.40,41 
Additional mutations, such as those transcription faca
tor abnormalities seen in good prognosis subtypes of 
AML, are required to cooperate with such tyrosine kia
nase mutations to cause fullablown murine leukemia 
in model systems.40,41 
Most studies have shown that internal tandem dua
plication mutations in the FLT3 confer adverse prognoa
sis.42,43 This is particularly true for AML patients with a 
normal karyotype. Activating mutations of FLT3 tend 
to be more common in those with a normal karyotype 
(17a30%).44,45 However these have also been reported 
in patients with the t(15;17) typical of acute promyeloa
cytic leukemia (APL), the t(6;9) translocation found in 
the rare entity of AML with basophilia and also with 
some other recurring cytogenetic abnormalities.37,45,46 
Clinical trials showed that FLT3-LM are strongly asa
sociated with leukocytosis, high blast counts, normal 
cytogenetics and t(15;17).38,47,66 In contrast, the FLT3-
LM are rarely found in patients with a complex karyoa
type and CBFaleukemias (CBFaMYH11 and AML1a
ETO). In almost all cytogenetic subgroups, the presa
ence of a FLT3-LM represents a negative prognostic 
risk factor for OS and EFS. It is controversial whether 
a FLT3 mutation is an independent negative prognostic 
factor in APL;48 moreover, studies have failed to show 
a consistent correlation between activation loop mutaa
tions and prognosis.49 However, Whitman et al have 
shown that the loss/deletion of the residual FLT3awild 
type (WT) allele predicts poor prognosis in adult de 
novo AML with normal cytogenetics and the internal 
tandem duplication of FLT3.25 These findings are also 
supported by data from Spiekerman et al showing that 
deletions of the FLT3aWT allele are more frequently 
found in patients at relapse as compared to patients at 
initial diagnosis suggesting that these genetic alterations 
are associated with disease progression.
Remarkable strategies to inhibit FLT3 signaling in 
development include antibodies50 and chaperone proa
tein inhibition51 to decrease the halfalife of the molea
cule, but the greatest interest has been in the small mola
ecule tyrosine kinase inhibitors including SU11248,30,52 
SU5416,31 CEP701,53 PKC41254 and MLN518. These 
tyrosine kinase inhibitors specifically kill leukemic cell 
lines transformed with either of the activated cona
structs of FLT3.29 Moreover, these agents have been 
shown to prolong the survival of mice with a fatal actia
vated FLT3amediated murine myeloproliferative disora
der.55 A number of structurally different FLT3 tyrosine 
kinase inhibitors (TKIs) have reached clinical trials in 
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elderly AML patients and/or relapsed refractory AML 
patients, some or all of whom had FLT3 mutations 
(Table 2).32,39,40,52a54 In most studies, the drugs have 
been well tolerated as monotherapy as outpatient oral 
medications. Usually there is more frequent response 
to FLT3 TKI in the mutant FLT3 patients. The rea
sponses in all patients, however, are usually short lived 
and restricted to a clearing of peripheral blasts for 
only few weeks to months. For example, clinical aca
tivity manifested as transient reductions in bone mara
row and peripheralablood blasts or longer periods of 
transfusion independence, was seen in 3 (60%) of 5 
patients with mutated FLT3 in a phase 2 trial of the 
FLT3 inhibitor lestaurtinib (CEP701) used as firsta
line treatment for older patients with AML who were 
not considered fit for intensive chemotherapy.56 Phase 
1 clinical trial results with tandutinib (MLN518), ana
other novel FLT3 antagonist, in patients with AML 
or higharisk MDS have also been reported.57 Eight 
of 40 patients had FLT3-ITD mutations. Two of the 
5 evaluable patients, treated at 525 mg and 700 mg 
twice daily, showed evidence of antialeukemic activity, 
with decreases in both peripheral and bone marrow 
blasts. Authors recommended tandutinib at the maxia
mum tolerated dose (525 mg twice daily) should be 
evaluated more extensively in patients with AML with 
FLT3-ITD mutations to better define its antialeukea
mic activity.57 However, major bone marrow responses 
are uncommon with these FLT3 inhibitors. This could 
be a result of genomic instability leading to multiple 
pathways of escape from dependence on FLT3 siga
naling. Each of these molecules inhibits FLT3 in the 
nanomolar range, but they vary in terms of chemical 
structure, preclinical side effect profile and most cona
spicuously, the spectrum of kinase which they inhibit. 
For example, PKC412 not only inhibits the FLT3 tyroa
sine kinase but it also inhibits cakit, and the serineathreoa
nine protein kinase C.58 Using an in vitro mutagenesis 
screen, Cool et al identified four different positions in 
the ATPabinding site of FLT3 that, when mutated, 
confer resistance to PKC412 (also called midostaua
rin), further documenting that resistance to PKC412 
can develop due to mutations in the kinase domain 
of FLT3.59 Most recently, Barry et al have reported 
that PKC412 is a potent inhibitor of a spectrum of 
FLT3 activation loop mutations, and that AML paa
tients with such mutations are potential candidates 
for clinical trials involving midostaurin.60 Midostaurin 
has shown activity in a phase 1 trial in combination 
with daunorubicin and cytarabine in newly diagnosed 
AML, in particular those patients with FLT3-ITD 
mutations.61
Levis et al have recently developed a useful surrogate 
assay for monitoring the efficacy of FLT3 inhibition in 
patients treated with oral FLT3 inhibitors. The plasa
ma inhibitory activity (PIA) for FLT3 correlates with 
clinical activity in patients treated with CEPa701 and 
PKC412.62 The application of this assay has revealed 
that the metabolite CGP52421 may contribute a siga
nificant portion of the antialeukemia activity observed in 
patients receiving oral PKC412. Additionally, the results 
suggested that nonaselectivity may constitute an impora
tant component of the cytotoxic effect of FLT3 inhibia
tors in FLT3amutant AML.62
With target identification followed by the demona
stration that activating mutations of FLT3 are pathoa
Table 2. Summary of  FLT3 inhibitors already tested in clinical trials.
FLT3 inhibitor Class FLT3  IC50** Other receptors Phase of clinical trial
CEP-701  
(lestaurtinib) Indolocarbazole 2 nM TRKA Phase III
PKC412  
(midostaurin) Indolocarbazole 10 nM KIT
Phase III (Intergroup 
trial is planned)
MLN518 (tandutinib) Quinazoline 30 nM KIT, PDGFR Phase II
SU5416 (sexamanib) 3-substituted indolinone 100 nM KIT, VEGFR Phase II
SU11248  (sunitinib) 3-substituted indolinone 50 nM KIT, PDGFR, VEGFR Phase I
CHIR-258 Benzimidalzole - quinoline 10 nM KIT,FMS, FGFR, VEGFR Phase I
ABT-869 NR 4 nM KIT, KDR, PDGFR Phase I
KW-2449 NR 6 nM FLT3, KIT, aurora kinase Phase I 
**IC50 is the concentration required for 50% inhibition of FLT3 autophosphorylation; NR: not reported
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physiologically relevant in AML, the development of 
FLT3 inhibitors as therapeutic agents to AML is an 
important progress. Although complexity of the disa
ease and patient population precluded their standard 
use as single agents in AML, it appears that the most 
widespread use of one or more of the FLT3 inhibitors 
in development in AML will come in conjunction with 
chemotherapy. Certainly randomized Phase III trials 
of chemotherapy with or without the FLT3 inhibia
tors are required but the major controversy is whether 
or not such trials should be conducted in selected 
groups of AML patients with an activating mutation 
of FLT3 where the greatest activity would be expecta
ed; or whether all AML patients should be included 
in such an evaluation because of the preliminary rea
sults showing activity in nonaFLT3 mutant patients 
as well as the possibility that the offatarget effects of 
these drugs might also be beneficial.58 Thus, it appears 
prudent argument to explore the interactive effect of 
FLT3-ITD mutations with other genetic aberrations 
in AML patients with normal cytogenetics. For exa
ample, Schnittger et al have raised the possibility that 
the cytoplasmic displacement of NPM1 protein by a 
multiplicity of frame shift mutations that introduce a 
common nuclear export signal may increase susceptia
bility to chemotherapyainduced apoptosis.20 This suga
gests that dynamic molecular analyses at both trana
scriptional and posttranscriptional levels early after 
exposure to chemotherapeutic agents with or without 
modulators, such as FLT3 inhibitors, might show difa
ferences between NPM1+FLT3a and NPM1+FLT3+ 
AML cells with normal cytogenetics that could implia
cate important target molecules.23 
Current trials are combining FLT3 inhibitors 
with conventional chemotherapy, but combinations 
of FLT3 TKI with other molecularly targeted agents 
affecting the other pathways could be the alternative 
goal. It is hoped that such trials will help in reversing 
the poor prognosis for AML patients with FLT3-ITD 
mutations by preventing relapse and reducing the toxa
icities associated with nonselective cytotoxic agents.
FLT3 may also be targeted specifically through 
antiaFLT3 antibodies.50,63 Fully human phage display 
antibodies were generated and selected for binding to 
human FLT3 and the ability to block FL binding to 
FLT3 in an ELISA assay. They have the ability to block 
signaling through wildatype FLT3 and also through 
some mutated forms of FLT3. They have been shown 
to induce antibody dependent cellularamediated cya
totoxicity (ADCC) and mediate killing of some, but 
not all, cell lines and primary samples of both AML 
and acute lymphoblastic leukemia (ALL) when used 
in vivo in nonaobese diabetic/severe combined immua
nodeficient (NOD/SCID) mice engrafted with these 
cells.64,65 AntiaFLT3 antibody trials are also being cona
sidered in AML patients especially those expressing 
mutant FLT3. Besides the potential for interfering 
with FLT3 signaling, antiaFLT3 antibodies can also 
induce ADCC as an additional mechanism for induca
ing cytotoxicity.63 
As mentioned earlier, in addition to FLT3-ITD, two 
types of point mutations in FLT3 localized within the 
activation loop of the tyrosine kinase domain (TKD) 
have been reported in 5% to 14% of AML patients with 
normal karyotype.20,45,66,67 In contrast to FLT3-ITD, the 
FLT3-TKD has not been reported to have an adverse 
prognosis among this subgroup of AML patients.45 
Rather interestingly, a small group of such patients beara
ing FLT3-TKD who concurrently had a mutation in the 
NPM1 gene had significantly longer EFS than patients 
without these mutations.20 However, further studies are 
necessary to determine the prognostic role of FLT3-
TKD, especially in relation to other molecular prognosa
tic factors in AML patients with normal karyotype.
Regarding the effect of transplantation on the outa
come of FLT3amutated patients, a consensus did not 
emerge from two retrospective studies68,69 In the MRC 
study conducted by Gale et al68 (35 patients with a mua
tation and 135 with no mutation), FLT-3 mutated status 
was also an adverse prognostic factor in the recipients 
of transplants. In this intentatoatreat analysis, (donor vs 
noadonor) transplantation reduced the relapse risk and 
improved the DFS, but the OS was not significantly 
improved. On this basis this study found no evidence 
to recommend transplantation based on FLT-3 status 
alone. On the other hand study by Bornhauser et al 
(Ulm group),69 the negative impact of FLT-3 mutation 
status was seen in patients who received chemotherapy 
or autologous transplantation, but not in the recipients 
of allogeneic HSCT. A major difference in the analya
sis was that the assessments were based on treatments 
given, rather than on an intent to treat that attempts 
to reduce selection of betterarisk patients entering the 
transplantation option.70
Partial tandem duplication (PTD) of the mixed 
lineage leukemia (MLL) gene
The mixed lineage/myeloid lymphoid leukemia (MLL) 
gene is located in chromosome band 11q23 covering a 
genomic region of approximately 100 kb of DNA and 
represents the human homologue of the Drosophila 
trithorax gene. The MLL gene is frequently involved 
in translocations that occur in AML and in ALL.71 
Rearrangement of the MLL gene detected by Southern 
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blot analysis was the first molecular marker described in 
patients with AML and normal cytogenetics.44
The majority of the translocation breakpoints clusa
ter in an 8.3akb region (breakpoint cluster region) that 
is represented by exons 5 to 11.71a73 MLL gene transa
locations, deletions, and duplications most often result 
in gene fusions between the 5’aend of the MLL gene 
and the 3’aend of a partner gene. The submicroscopic 
rearrangements of the MLL gene are the partial tana
dem duplications of MLL (MLLaPTD). At the level 
of transcription MLLaPTD result in a unique inaframe 
fusion of exons 11 or 12 upstream of exon 5. Functional 
data support the hypothesis that MLLaPTD induce a 
loss of MLL WT function via monoallelic repression, 
thereby contributing to the leukemic phenotype by the 
remaining mutant allele. 
However, the pathogenetic relevance of this gene reara
rangement in AML is still not clear as Marcucci et al74 
and Schnittger et al,75 using nested reverse transcriptase 
polymerase chain reaction (RTaPCR), demonstrated dea
tectable PTD of the MLL gene with different frequena
cies in peripheral blood (PB) and BM of healthy donors. 
Strout et al76 have shown that molecular rearrangea
ment in patients with normal cytogenetics is a tandem 
duplication of an internal portion of the MLL gene that 
spans exons 2 to 6 or exons 2 to 8 in most of the cases. 
This PTD was detected in approximately 10% of AML 
with normal cytogenetics and in 90% of AML exhibita
ing trisomy 11 (+11) as a sole chromosome abnormala
ity.72,77 By dosage analysis, it was shown that in the cytoa
genetically normal cases and in the cases with +11, only 
one chromosome 11 contained the mutated allele.78
Caligiuri et al79 analyzed 98 patients with de novo 
AML and normal karyotype for PTD of the MLL gene 
by Southern blot analysis and singlearound RTaPCR. 
In this study, 11 (11%) of 98 patients showed a PTD. 
PTDapositive patients who achieved CR had a statistia
cally significant shorter CR duration (7.1 months) coma
pared with the PTDanegative patients (23.2 months). 
In another study,80 the incidence of MLL PTD was 
lower than previously reported, but in agreement with 
the findings of Caligiuri et al.79 PTD of the MLL gene 
was associated with an unfavorable prognosis. 
Lately, Dohner et al in a large prospective series of 
newly diagnosed young adult patients (16 to 60 years 
of age) with AML treated within the multicenter treata
ment trials AMLaHD93 and AMLaHD98A of the 
AML Study Group81,82 have shown that within the suba
group of patients with normal karyotype, MLL PTD is 
associated with short remission duration.82 MLL PTD 
was identified in none of the 129 patients with t(8;21), 
inv(16), and t(15;17); in 19 (7.7%) of 247 patients with 
normal karyotype; and in 10 (8.5%) of 119 patients 
with all other abnormalities, while 30 cases of t(11q23) 
were excluded. The median remission durations of the 
PTDapositive and the PTDanegative groups were 7.75 
months and 19 months, respectively (P<.001) and mula
tivariate analysis identified the MLL PTD status as the 
single prognostic factor for remission duration.82
In summary, MLLaPTD are frequently found in 
adult de novo AML and are associated with a worse 
prognosis (i.e., shorter duration of remission) when 
compared with normal karyotype AML without the 
MLL PTD. In addition, several studies have shown that 
MLLaPTD are more frequently found in FLT3-ITD 
positive compared to FLT3-ITD negative patients.
BAALC (brain and acute leukemia, cytoplasa
mic) overexpression is a gene located at chromosome 
8q22.3. It encodes a protein of yetaunknown function. 
Normally, BAALC is almost exclusively expressed in 
neuroectodermaderived tissues. In addition, CD34a
positive progenitor cells from normal and abnormal 
bone marrow express BAALC, identifying it as another 
gene whose expression is shared by neural and hematoa
poietic cells. In hematopoiesis, BAALC reflects a stagea
specific marker as downregulation of BAALC occurs 
with cell differentiation. As all subtypes of CD34+ cells 
express BAALC, it is postulated that BAALC reprea
sents a novel marker of an early progenitor cell coma
mon to the myeloid, lymphoid, and erythroid pathways. 
It is aberrantly expressed in a subset of acute leukea
mias.46,83,84 Tanner et al reported BAALC overexpresa
sion in 12 of 63 patients with normal karotype (19%). 
Overexpression of BAALC was an adverse prognostic 
factor.83 In a CALGB study of 86 de novo AML paa
tients younger than 60 years with a normal cytogeneta
ics and more favorable FLT3 mutation status, high 
mRNA expression levels of BAALC were shown to 
be an adverse risk factor.85 There was no significant difa
ference in response to induction therapy between the 
two cohorts as 81% of low BAALC and 77% of high 
BAALC expressers achieved CR.85 However, AML paa
tients with high BAALC expression tended to relapse 
more frequently than those with low BAALC expresa
sion (52% versus 29%). High BAALC expression prea
dicted significantly shorter OS (median, 1.7 versus 5.8 
years, P=.02). Eventafree survival also was significantly 
shorter in patients with high BAALC expression coma
pared to those with low BAALC expression (median, 
0.8 versus 4.9 years, P=.03), as was DFS (median, 1.4 
versus 7.3 years, P=.03).85
A recent study by Baldus et al46 on 307 AML paa
tients ( 60 years of age with normal cytogenetics enrolled 
in the Deutsche Studies Initiative Leukämie (DSIL) 
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has confirmed that as compared to patients with lowa
BAALC expression, patients with highaBAALC expresa
sion had a higher rate of primary resistant leukemia 
(16% v 6%; P=.006),46 a higher cumulative incidence of 
relapse (CIR; P=.018) and an inferior OS (3ayears, 36% 
v 54%; P=.001). High BAALC expression was associa
ated with a higher percentage of blood blasts (P=.004) 
and more immature FAB subtypes M0/M1 (P=.001) 
while monocytic differentiation FAB M5b and gingival 
hyperplasia were more frequent in low BAALC patients 
(P=.001 and .003, respectively). Although high BAALC 
expression was associated with a higher percentage of cira
culating blasts, and both variables were associated with 
poor outcome in the univariate analysis, in multivariate 
analyses only high BAALC was independently predica
tive of resistant disease (P=.019).46 Additionally this 
study demonstrated that high BAALC is significantly 
associated with a higher FLT3 ratio (FLT3 mutant:wild 
type ratio). For most AML patients (i.e. those with a low 
risk FLT3 mutation status) BAALC expression allowed 
further discrimination of higha and lowarisk patients. 
Importantly, in multivariable analysis high BAALC and 
a high FLT3 mutant:wild type ratio were independently 
predictive of inferior OS and higher CIR. As both faca
tors independently influenced the clinical course, differa
ent molecular pathways may be involved.46 This study 
showed high BAALC expression as one of the impora
tant independent risk factors associated with resistant 
disease, a high CIR, and inferior survival. Modulation of 
induction therapy and intensification of postremission 
therapy may be critical to improve outcome for these 
higharisk patients. This study suggested that patients 
with high BAALC expression may benefit from cona
solidation with allogeneic SCT but not with autologous 
SCT. This is because in high BAALC patients undera
going allogeneic SCT a low 3ayear CIR (16%) was oba
served compared with highaBAALC patients receiving 
autologous SCT (52%; P=.007).46 
Recently CALGB group confirmed that high 
BAALC expression is an independent adverse proga
nostic factor and is associated with a specific geneaexa
pression profile.86 They analyzed BAALC expression in 
172 primary CNaAML patients younger than 60 years 
of age, treated similarly on CALGB protocols. High 
BAALC expression was associated with FLT3-ITD 
(P=.04), wildatype NPM1 (P<.001), mutated CEBPA 
(P=.003), MLLaPTD (P=.009), absent FLT3aTKD 
(P=.005), and high ERG expression (P=.05). In a 
multivariate analysis, high BAALC expression indea
pendently predicted lower complete remission rates 
(P=.04) when adjusting for ERG expression and age, 
and shorter survival (P=.04) when adjusting for FLT3-
ITD, NPM1, CEBPA, and white blood cell count. A 
geneaexpression signature of 312 probe sets differentia
ating high from low BAALC expressers was identified. 
High BAALC expression was associated with overexa
pression of genes involved in drug resistance (MDR1) 
and stem cell markers (CD133, CD34, KIT).86
ETS-related gene (ERG) overexpression
ETSarelated gene (ERG), which is located at chromoa
some band 21q22, is frequently overexpressed in AML 
patients with complex karyotypes and cryptic amplifia
cation of chromosome 21.87 ERG is one of more than 
30 members of the ETS gene family, most of which are 
downstream nuclear targets of signal transduction patha
ways regulating and promoting cell differentiation, proa
liferation, apoptosis and tissue invasion.88a90 Although 
ERG rearrangements have been found in AML91 and 
Ewing sarcoma92 and its overexpression has been oba
served in prostate cancer,93 little is known regarding 
how ERG contributes to malignant transformation.94 
Baldus et al reported earlier that high ERG expression 
was not always associated with genomic amplification, 
thereby leaving ERG overexpression mechanistically 
unexplained.87 Nevertheless, the recurrent presence of 
ERG overexpression in AML with complex karyotypes, 
a prognostically unfavorable subgroup, suggests that 
ERG overexpression might not only be a nonrandom 
event in myeloid leukemogenesis, but also might cona
tribute to an aggressive malignant phenotype. 
Marcucci et al from CALGB44 recently tested the 
prognostic significance of ETSarelated gene (ERG) 
expression in cytogenetically normal primary AML 
patients (N=84) who were uniformly treated on the 
Cancer and Leukemia Group B (CALGB) 9621 protoa
col. ERG overexpression predicted an increased relapse 
risk and short survival in AML patients with normal 
karyotype by both univariate and multivariate analyses 
and seemed to be associated with a specific molecular 
signature.44 With a median followaup of 5.7 years, paa
tients with the upper 25% of ERG expression values 
had a worse CIR (P<.001) and OS (P=.011) than 
the remaining patients. In a multivariate analysis, high 
ERG expression (P<.001) and the presence of MLL 
PTD (P=.027) predicted worse CIR. With regard to 
OS, an interaction was observed between expression of 
ERG and BAALC (P=.013), with ERG overexpression 
predicting shorter survival only in low BAALC expressa
ers (P=.002). ERG overexpression was an independent 
prognostic factor even when the unfavorable group of 
FLT3-ITD patients lacking an FLT3 wildatype allele 
was included. High ERG expression was associated 
with upregulation of 112 expressedasequenced tags and 
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named genes, many of which are involved in cell prolifa
eration, differentiation, and apoptosis.44
More recently, Marcucci et al have validated ERG 
overexpression as an adverse predictor in cytogenetically 
normal AML patients (seen in 37% of such patients).96 
Moreover, by using ERG expression levels, previously 
proposed moleculararisk classification of cytogenetia
cally normal AML (based on the presence or absence of 
FLT3-ITD and NPM1 mutations) could be improved 
as they identified subsets with different outcome among 
FLT3aITDanegative patients, NPM1apositive patients, 
and FLT3aITDanegative/NPM1apositive patients aca
cording to ERG expression level.96 
Mutations of the CCAAT enhancer-binding pro-
tein α (CEBPA) gene
CEBPA is a single exon gene located in the chromosome 
region 19q 13.1 that encodes CCAAT enhancerabinda
ing protein α (CEBPα), a member of the basic region 
leucine zipper (bZIP) class of transcription factors and 
consist of highly homologous Caterminal DNAabinda
ing (basic region) and dimerization (leucine zipper) moa
tifs and two lessaconserved Naterminal transactivation 
domains. On the basis of the observation that CEBPαa
deficient mice lack mature granulocytes,97 it has been 
speculated that CEBPA mutations might contribute to 
the differentiation block specific to AML. Conditional 
expression of CEBPα induces a number of granulocyte 
specific genes that induce differentiation, while knocka
out mice exhibit an early block in maturation.
An alternative mechanism for CEBPα inactivation 
has been described in AML patients with t(8;21), where, 
the AML 1aETO fusion protein suppresses CEBPα 
transcription and hence blocks granulocyte differentiaa
tion.98 Mutations in the CEBPα gene can be detected 
in 7% to 15% of patients with AML mostly in the FABa
M2 subtype and the majority of patients with mutations 
had normal cytogenetics.99,100 The favorable prognostic 
impact of CEBPA mutation has been suggested by seva
eral studies. Preudhomme et al101 examined pretreata
ment samples from 135 adults and identified different 
types of mutations in 15 (16%) of 91 patients with ina
termediatearisk cytogenetics. The presence of a CEBPA 
mutation was associated with significantly better clinical 
outcome. van Waalwijk from the Netherlands, screened 
277 patients for mutations in the bZIP domain. Ina
frame insertions were identified in 12 patients (4%; eight 
patients with normal cytogenetics and four patients with 
other chromosome abnormalities) and were subsequenta
ly shown to coincide with Naterminal mutations on the 
other allele. Among the 187 patients with intermediatea
risk karyotypes, patients with the mutations had signifia
cantly increased EFS and OS.102
More recently, Frohling et al assessed the prognostic 
significance of CEBPA mutation on 236 AML patients, 
16a60 years of age with normal cytogenetics.103 CEBPA 
mutations were detected in 15% of the 236 patients and 
9% had mutations predicted to result in loss of CEBPA 
function.103 Remission duration and OS were signifia
cantly longer for the 36 patients with CEBPA mutaa
tions (P=.01 and P=.05, respectively). By multivariate 
analysis, wildatype CEBPA was an independent adverse 
prognostic marker affecting remission duration (hazard 
ratio, 2.85; P=.01) and OS (hazard ratio, 1.87; P=.04). 
In their analysis of cooperating mutations (both types 
of activating FLT3 mutations and MLL partial tandem 
duplications) showed that FLT3 mutations had no siga
nificant prognostic influence in patients with CEBPA 
mutations.103 The above data consistently support the 
favorable outcome of CEBPA mutations in AML paa
tients with normal cytogenetics. 
Meningioma 1 (MN1) overexpression
The meningioma 1 (MN1) gene, localized on hua
man chromosome 22, was first cloned in 1995 
from a patient with meningioma with translocation 
t(4;22)(p16;q11).104 It is disrupted in balanced transa
location. The translocation t(12;22) involves TEL and 
MN1 and is rarely found in AML. It has been shown in 
a mouse model that the fusion protein TELaMN1 can 
promote growth of primitive hematopoietic progenia
tor cells (HPCs)105 and, in cooperation with HOXA9, 
which is overexpressed in patients with AML,106 may 
induce AML.105 Heuser et al from Germany recently 
quantified MN1 expression by realatime reverse trana
scriptaseapolymerase chain reaction (RTaPCR) in 142 
adult patients with AML with normal cytogenetics 
treated uniformly in trial AMLaSHG 01/99.107 AML 
samples were dichotomized at the median MN1 exa
pression. High MN1 expression was significantly correa
lated with unmutated NPM1 (P<.001), poor response 
to the first course of induction treatment (P=.02), a 
higher relapse rate (P=.03), and shorter relapseafree 
(P=.002) and OS (P=.03). In a multivariate analysis, 
MN1 expression was an independent prognostic marka
er (P=.02) in addition to age and Eastern Cooperative 
Oncology Group (ECOG) performance status. 
Excluding patients with NPM1mutated/FLT3-ITD 
negative, high MN1 expression was associated with 
shorter relapseafree survival (P=.057). MN1 was highly 
expressed in HPCs compared with differentiated cells 
and was downaregulated during in vitro differentiation 
of CD34+ cells, suggesting a functional role in HPCs. 
Heuser et al concluded that MN1 overexpression may 
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serve as a new prognostic marker in AML with nora
mal cytogenetics.107 However, these findings are yet to 
be verified by further studies. The negative impact of 
MN1 overexpression in elderly AML patients (leada
ing to allatrans retonoic acid resistance) is further disa
cussed below. 
RAS mutations
RAS (rat sarcoma) gene mutations were first reported 
in AML patients 18 years ago,108,109 but the prognosa
tic impact of NRAS mutations in AML is still under 
debate. RAS oncogenes encode a family of membranea
associated proteins that regulate signal transduction on 
binding to a variety of membrane receptors. There are 
three functional RAS genes: Na(from a neuroblastoma 
cell line), Ka(Kirsten), and Ha(Harvey) RAS, each 
containing 4 exons and all homologs carry mutations 
nearly exclusively in codons 12, 13, and 61, conferring 
constitutive activation of the RAS protein. NRAS mua
tations seem to be the most prominent RAS mutations 
in patients with AML and have been reported in 11% 
to 30% of patients.110a118 They lead to increased activity 
of the RAS pathway, resulting in increased proliferation 
and decreased apoptosis rates.114 
Some studies indicate an association with poor outa
come in general,119,120 or in only those AML patients 
who had a favorable karyotype.112 In contrast, Neubauer 
et al111 found NRAS mutations associated with a favora
able prognosis, whereas in some studies a prognostic 
impact of NRAS mutations could not be defined at 
all.114a116 Some studies did not find a significant assoa
ciation of NRAS mutations with certain cytogenetic 
subgroups.111,113 To clarify the biologic and prognostic 
impact of NRAS mutations, Bacher et al110 recently 
analyzed a large cohort of 2502 patients with AML 
who were well characterized with respect to cytomora
phology, cytogenetics, and other molecular mutations. 
Two hundred fiftyaseven (10.3%) of 2502 patients had 
NRAS mutations (NRASmut). Most mutations (112 of 
257; 43.6%) were found at codon 12, mostly resulting 
in changes from glycine to asparagine. These included 
109 of 1198 patients with normal karyotype, (9.1%). 
Overall, they did not find a significant prognostic ima
pact of NRASmut for OS, EFS, and diseaseafree sura
vival DFS. However, detailed analyses of KaplanaMeier 
plots in the NRASmut cohort showed a trend to reach 
a plateau after 1 year of followaup in normal karyotype, 
t(8;21) and inv(16) according to OS analysis.110 
Taking other molecular markers (FLT3-LM, MLLa
PTD, NPM1) into account in this group indicated an 
even better trend for a more favorable prognosis. In the 
total cohort without FLT3 mutations, EFS was slightly 
improved for patients with NRAS mutations (426 ± 73 
days) compared with patients negative for NRAS mutaa
tions (378±21 days) (P=.060).110 
Mutations in Wilms tumor 1 gene (WT1)
The Wilms tumor gene (WT1) located on chromoa
some 11p13 encodes a transcription factor, which is 
involved in control of growth and differentiation of 
various cell types including hematopoietic cells.121 
Another study revealed that WT1 expression levels 
in normal hematopoietic progenitor cells were at least 
10 times less than those in leukemic cells indicating 
an aberrant overexpression of the WT1 gene in leukea
mic cells and implying the involvement of this gene in 
human leukemogenesis.122 WT1 mutations in AML 
were first reported in 1998.123 Disruption of WT1 
function by mutation of the gene could either promote 
proliferation or induce a block in differentiation. In a 
recent study of 70 patients having AML with normal 
cytogenetics, WT1 mutations were detected in 10% 
of the patients.124 They found that the mutations cona
sisted of insertions or deletions that mainly clustered 
in exons 7 and 9. The WT1 mutations were associata
ed with FLT3-ITD and failure of standard induction 
chemotherapy in this study.124 However, the impact of 
WT1 mutations needs to be evaluated in larger series. 
Murine and early human studies suggest that WT1 
protein can serve as a target antigen for tumoraspecific 
immunity.125 The WT1 is a reliable marker for MRD 
assessment in acute leukemia patients. The evaluation 
of WT1 in peripheral blood samples after induction 
chemotherapy can distinguish the continuous coma
plete remission patients from those who obtain only an 
“apparent” complete remission and who could relapse 
within a few months. WT1 helps identify patients at 
high risk of relapse soon after induction chemotherapy 
allowing postainduction therapy in higharisk patients 
to be intensified.126
Many other genes mutations, such as inactivating 
mutations of the ubiquitin ligase CBL, have been ima
plicated to have clinical relevance in AML with nora
mal cytogenetics, but the prevalence and clinical rela
evance, if any, of such gene mutations, remain to be 
determined.127a129
Interactions among prognostically important genes
Most of the above cited studies have focused on the 
prognostic value of single markers, not taking into aca
count their potential interactions. However, as our 
knowledge is improving, later studies have tried to exa
plore interaction of various prognostically important 
genes in AML patients.20a24,110,130,131 For example, in the 
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study by Bacher et al110 the impact of NRAS mutations 
on OS in AML patients with normal karyotype was faa
vorable after 1 year and when other molecular markers 
(FLT3-LM, MLLaPTD, NPM1) were taken into aca
count the cohort indicated an even better trend for a 
more favorable prognosis. 
Very recently Schlenk et al registered 872 patients 
(16 to 60 years of age) with normal karyotype AML130 
from four AMLSG treatment trials (AMLa2/95, AMLa
1/99, AML HD93, AML HD98A) and obtained tua
mor samples from most. Several genes were examined 
for mutations including: NPM1, FLT3 (FLT3-ITD 
and FLT3aTKD), CEBPA, MLL (PTD), and NRAS. 
Using a logistic regression model, two mutation coma
binations were identified as predicting response to ina
duction therapy: NPM1+/FLT3-ITDa and CEBPA+. 
Cox proportional hazard models were then constructed 
to identify prognostic factors for relapseafree survival 
(RFS) and OS. Age <48 years, the availability of a 
matchedarelated donor, and in particular the NPM1+/
FLT3-ITDa (hazard ratio of 0.34 and 0.43 for RFS 
and OS survival respectively) and CEBPA+ genotypes 
(hazard ratio 0.42 and 0.36), were all associated with 
improved outcomes. Interestingly, in those patients 
with the NPM1+/FLT3-ITDa genotype combination, 
the availability of a matchedarelated donor did not apa
pear to confer a significant survival advantage (HR 0.89 
and 0.93 for RFS and OS, respectively). In contrast, 
for those patients possessing all other combinations of 
NPM1 and FLT3-ITD, 4ayear RFS was significantly 
higher in those with a matchedarelated donor (47%) 
versus those without a donor (23%). This implies that 
allogeneic HSCT in first CR does offer benefit over 
standard postaremission therapy in normal karyotype 
AML, but only in those without the NPM1+/FLT3-
ITDagenotype.130
A study by Schlenk et al is pioneering in that it cona
currently included multiple genetic markers in its proga
nostic modeling. The hazard ratios for the NPM1+/
FLT3-ITDa and CEBPA+ genotypes are particularly 
impressive and appear to strongly predict a subset of 
normal karyotype AML patients destined for good clina
ical outcomes. More recently Schlenk at al compared 
the mutational status of the NPM1, FLT3, CEBPA, 
MLL, and NRAS genes in leukemia cells with the clinia
cal outcome in 872 adults younger than 60 years of age 
with cytogenetically normal AML.131 The overall CR 
rate was 77%. The genotype of mutant NPM1 without 
FLT3-ITD, the mutant CEBPA genotype, and younger 
age were each significantly associated with higher CR 
rate.131 Of the 663 patients who received postremisa
sion therapy, 150 underwent HSCT from an HLAa
matched related donor. The risk of relapse or the risk 
of death during complete remission were lower with the 
leukemia genotype of mutant NPM1 without FLT3-
ITD (hazard ratio, 0.44), the mutant CEBPA genoa
type (hazard ratio, 0.48), while such risks were higher 
with the MLLaPTD genotype (hazard ratio, 1.56).131 
Receipt of a transplant from an HLAamatched related 
donor lowered the risk of death and relapse (hazard 
ratio, 0.60) in the subgroup of patients with the proga
nostically adverse genotype FLT3-ITD or the genotype 
consisting of wildatype NPM1 and CEBPA without 
FLT3-ITD.131 
As two or more genetic alterations can be present 
simultaneously in AML patients with normal cytogea
netics, part of the validation process of a newly discova
ered predictor is to prove that it can maintain an indea
pendent prognostic value when assessed against other 
molecular markers. However, one of the limitations of 
this type of approach, often lies in the small number 
of patients available for subset analyses, so researchers 
have attempted to combine data from various trials to 
get meaningful results.96
Recent data from Marcucci et al96 indicate that 
FLT3-ITDanegative/NPM1apositive patients, consida
ered to have a favorable prognosis, can be separated into 
prognostic subsets based on expression levels of ERG. 
They suggest that FLT3-ITDanegative/NPM1aposia
tive/low ERG patients are likely to benefit from higha
dose cytarabine and autologous peripheralablood stema
cell transplantationabased therapies as administered in 
CALGB 9621 and 19808.96 In contrast, FLT3-ITDa
negative/NPM1anegative/high ERG patients perhaps 
should be considered for alternative and/or more aga
gressive treatments, because their estimated 2ayear EFS 
is less than 40%. Similarly, cytogenetically normal AML 
patients with FLT3-ITD who have a poor prognosis 
should be considered for clinical trials investigating 
compounds that directly inhibit FLT3 tyrosine kinase 
activity or for allogeneic SCT, although a definitive role 
for the latter in first CR remains to be established.96
A few markers are about to enter clinical practice, in 
particular in the context of clinical trials. For instance, 
activating FLT3 mutations, in particular in AML 
with normal cytogenetics, have prognostic significance 
and, importantly, are attractive targets for molecularly 
targeted therapy. The first randomized studies using 
TK inhibitors in these patient subsets have started. 
Furthermore, two genotypes, NPM1mut/FLT3-ITDneg 
and CEBPAmut, have been identified that are associated 
with a favorable risk profile, comparable with that of 
coreabinding factor (CBF) AML. Patients whose AML 
harbor such genotypes may not benefit from allogeneic 
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SCT in firstaline treatment. These data have important 
implications since the two genotypes represent approxia
mately 45% of patients with cytogenetically normal 
(CN)aAML and 20% of all patients with AML. As a 
consequence, NPM1, FLT3 and CEBPA mutational 
screening should become part of the initial workaup of 
a newly diagnosed AML.
 Although such clinical outcome models will ultia
mately require further refinement and prospective valia
dation, they appear to provide a new tool with which 
hematologists can identify those most likely to benefit 
from upfront allogeneic HSCT and spare goodaproga
nosis patients from unnecessary transplantarelated 
morbidity.130,132 There have been suggestions that a clasa
sification of AML incorporating molecular markers will 
emerge soon.133,135
We propose that as the number of such genetic 
aberrations is growing and we are accumulating infora
mation about the relative impact of each aberration 
on clinical outcome, a scoring system incorporating all 
such markers may be desirable for prospective decision 
making. This exciting new information may allow for a 
more tailored therapeutic approach to such patients in 
the near future.
Some peculiarities of genetic alterations in el-
derly patients
AML occurring in patients older than 55 to 60 years 
of age is characterized by profound biologic differences, 
including the distribution, but not the spectrum, of 
cytogenetic abnormalities. In particular, favorablearisk 
aberrations are relatively uncommon in the elderly, as 
opposed to normal and complex karyotypes. However 
in absolute terms the intermediatearisk cytogenetics 
group including those with normal karyotype constia
tutes the largest proportion (58%) of even the elderly 
patients with AML.136
At the molecular level, mutations in the FLT3, RAS, 
and TP53 (p53) genes are relatively common in elderly 
patients with AML, with estimated prevalences of 27%, 
16%, and 10%, respectively.137 However, it is not clear 
if these FLT3-ITD and point mutations in the activaa
tion loop of the FLT3aTKD (such as the D835Y mua
tation) are independent predictors of the prognosis of 
elderly AML patients. In a SWOG study on the outa
come of 140 elderly patients treated with daunorubicin 
and cytarabine on SWOG S9031.137 The FLT3 ITD 
was detected in 34% of these patients. However, in 105 
patients with complete cytogenetic and MDR1 data, 
FLT3 mutational status did not provide any additional 
prognostic information for achievement of CR after 
controlling for age, leukocytosis, blast karyotype, and 
MDR1 expression. FLT3 ITD was associated with a 
lower risk of resistant disease. Similarly the presence of 
FLT3 ITD did not significantly affect the CR rate, CR 
duration, or overall survival of patients more than 60 
years old treated with highadose cytarabineabased regia
mens at M. D. Anderson Cancer Center.67
Another study comparing 381 patients having 
MDS and 4130 patients with AML (de novo: n=3139; 
secondary AML following MDS: n=397; therapyarea
lated: n=233; relapsed: n=361) has shown that the 
frequency of FLT3alength mutations, FLT3aTKD, 
MLLaPTD, NRAS, and KITD816 increase from lowa 
to higharisk MDS, to secondary AML, and to relapsed 
AML emphasizing the value of these mutations as 
markers of progressing disease.95 As AML arising from 
MDS is a more common event in the elderly, progresa
sive age intuitively may also lead to accumulation of 
molecular genetic lesions in the elderly AML patients 
having normal cytogenetics.
As described above, MN1 is a unique oncogene in 
hematopoiesis that both promotes proliferation/selfa
renewal and blocks differentiation. It may become usea
ful as a predictive marker in AML treatment, particua
larly in elderly patients. Heuser et al recently evaluated 
whether MN1 expression levels in patients with AML 
(excluding M3aAML) correlated with resistance to 
ATRA treatment in elderly patients uniformly treated 
within treatment protocol AMLHD98aB.138 Strikingly, 
patients with low MN1 expression who received ATRA 
had a significantly prolonged eventafree (P=.008) and 
overall (P=.04) survival compared with patients with eia
ther low MN1 expression and no ATRA, or high MN1 
expression with or without ATRA. Hence in this study 
high MN1 expression in patients with NonaM3AML 
was associated with ATRA resistance, whereas patients 
with low MN1 expression survived significantly longer 
when ATRA was added to standard chemotherapy.138
Overall, these data suggest that the ability of ela
derly patients to tolerate induction chemotherapy 
may be a more important factor in addition to age, 
leukocytosis, blast karyotype, and MDR1 expresa
sion.67,137 Obviously, these facts have great implicaa
tions in planning therapies for this special population. 
There is a need to further explore therapeutically rela
evant molecular genetic lesions and more effective but 
less toxic targeted therapies for the elderly AML paa
tients with normal cytogenetics. As described above, 
NPM1, FLT3 and CEBPA mutational screening and 
MN1 expression assessment may soon become part of 
the initial workaup of a newly diagnosed AML patient 
and may help in improving the stratification of elderly 
AML patients with normal cytogenetics.
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Gene expression profiling in the subclassifica-
tion of AML with a normal karyotype 
Genomic approaches have altered the landscape of 
medical research and have potential to transform clinia
cal practice. Although the established genetic markers 
like NPM, FLT3, CEBPA, BAALC, MLL and NM1 
have substantially improved the potential for subclasa
sification of AML with a normal karyotype further ina
sights into the molecular heterogeneity are necessary. 
To find molecular signatures that identify prognostic 
subgroups, microarray gene expression profiling has 
been used as it may help not only in the development 
of models of outcome prediction, but also in predicting 
therapyarelated toxicity, identifying new pathways of 
disease pathogenesis and potential targets for therapy. 
The DNA microarray (complementary DNA and 
oligonucleotide) has been a critical tool for genomica
based approaches to generating information about 
tens of thousands of genes for a given sample. This 
generation of vast amounts of data has much potential 
but many challenges. One of the early challenges has 
been the development of analytical tools to interpret 
thousands of data points for relatively few samples. 
Analytical techniques have principally focused on sua
pervised and unsupervised learning. Supervised learna
ing approaches use known class labels (i.e. tumor type 
and relapse status) to identify genes whose expression 
correlates with the class label. As such, supervised 
learning has been used for class prediction and the 
the assignment of a sample to an already defined class. 
Unsupervised learning assumes no prior knowledge of 
sample label and rather groups samples together based 
solely on gene expression status. Unsupervised learna
ing has been used for new class discovery.139
Few recent studies have addressed this topic in rea
lation to cytogenetically normal AML patients. In a 
study by Valk et al, AML patients with a normal karyoa
type were grouped into several clusters, three of which 
accounted for at least 75% of patients.140 Using cDNA 
microarrays Bullinger et al profiled 116 diagnostic 
AML samples and could show that AML patients with 
a normal karyotype can be divided in two subgroups 
with different OS.141 Bullinger et al, with unsupera
vised and supervised learning algorithms, developed a 
clinical outcome predictor validated in an independent 
data set. This expressionabased predictor identified 
good versus poor outcome with statistical significance 
whether applied to patients with known cytogenetic 
abnormalities or to those with a normal karyotype. 
Radmacher et al from CALGB recently validated proga
nostic association of Bullinger’s signature in normal 
karyotype AML patients, using a different platform 
(Affymetrix U133) for measuring oligonucleotide mia
croarrays gene expression.142 This expression signature 
is the first outcome predictor for patients with intera
mediatearisk AML. However, clustering can be applied 
to a set of patients but not for subsequent individual 
patients as adding a patient can affect formation of 
clusters and thus change the rules by which each paa
tient is classified. For outcome prediction of individua
als, we need a rule unaffected by adding new patients. 
For example, compound covariate prediction (CCP) 
is one of many statistical techniques that may be used 
to assign individual patients to poor or good outcome 
groups. Radmacher et al used CCP to assign patients 
to poor or good outcome groups using the Bullinger 
signature139,142 and they were able to develop a classia
fier that predicts outcome (good vs poor) in terms of 
DFS and OS. Notably this particular signature seems 
to be highly affected by FLT3 ITD as a classifier does 
not discriminate FLT3 ITD+ patients well, but apa
pears to identify patients in FLT3 WT group who will 
have lower survival but prediction accuracy here was 
moderate.139,142 Very recently Bullinger et al have disa
covered the geneaexpression patterns that correlated 
with FLT3-ITD mutation and evaluated the utility of 
their FLT3 signature (composed of 20 genes) for proga
nostication in AML patients with normal cytogeneta
ics.134 Their predictor exhibited modest performance 
(73% sensitivity; 85% specificity) in classifying FLT3-
ITD status. The signature outperformed FLT3-ITD 
mutation status in predicting clinical outcome. These 
findings support the potential clinical utility of a gene 
expressionabased measure of FLT3 pathway activation 
in AML.134 
Bullinger et al earlier profiled gene expression of 138 
samples of adult AML patients with normal karyotype 
using DNA microarray technology.143 All samples anaa
lyzed were derived from AML patients entered within 
the randomized multicenter treatment trial HDa98A of 
the GermanaAustrian AML Study Group (AMLSG). 
Based on supervised data analyses they were able to 
identify a 116agene comprising expression pattern cora
related with NPM1amutated and FLT3 ITDanegative 
AML cases. The NPM1amutated/FLT3 ITDanegative 
pattern was also in part characterized by a prominent 
HOX gene cluster, which clearly separated the NPM1a
wild type from the NPM1amutated cases. As expected, 
the NPM1aunmutated cases displayed higher BAALC 
and MN1 expression and the newly defined signature 
also defined a NPM1amutated group that did not cona
tain many FLT3 ITDapositive samples. Moreover, they 
identified several other genes of potential pathogenic 
relevance which also have been previously shown to be 
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predictive in normal karyotype AML. These findings 
support a distinct molecular mechanism associated 
with the favorable outcome of NPM1amutated/FLT3 
ITDanegative AML cases.143 Such reported signatures 
might contribute to improved risk stratification and 
clinical management of AML patients with normal 
karyotype. While many challenges remain to be overa
come, a combination of gene expression profiling with 
other microarrayabased applications, highathroughput 
mutational analyses and proteomic approaches will 
also give important insights into the true pathobiologic 
nature of this type of leukemia. 
DNA microarray technology matured in the mida
1990s, and the past decade has witnessed a tremena
dous growth in its application as a powerful tools for 
researchers seeking to describe, classify, and undera
stand human disease. There are great expectations 
that the technology would advance the AML research. 
Some challenges remain in translating this technology 
in clinical practice to confirm if different signaturea
based classifiers more accurately predict outcome for 
individual patients and determine how it can be used 
to stratify patients for riskaadapted treatments.
Conclusions
For adult patients with AML, karyotype is the strona
gest predictor of treatment outcome. AML with normal 
karyotype is usually grouped in the “intermediate risk” 
category. The treatment outcome of AML with normal 
karyotype is extremely heterogeneous. Accordingly, 
there has been a recent interest in using molecular 
markers to risk stratify these patients. Available new 
technologies such as gene expression profiling have ima
proved our knowledge about potentially altered genes 
and their prognostic impact. It can be foreseen that 
these newly recognized molecular markers will soon 
become part of diagnostic/prognostic workup routine 
for AML patients with normal cytogenetics. There have 
been suggestions that soon a classification of AML ina
corporating molecular markers will emerge. 
Eventually, these molecular findings will be used to 
stratify patients for riskaadapted and targeted treata
ments. With target identification followed by the 
demonstration that activating mutations of FLT3 are 
pathophysiologically relevant in AML, the developa
ment of FLT3 inhibitors (and other tyrosine kinase ina
hibitors) as therapeutic agents for AML patients with 
normal cytogenetics is an important step. It appears 
that the most widespread use of these tyrosine kinase 
inhibitors showing activity in AML patients will come 
in conjunction with chemotherapy. 
Although proposed clinical outcome models incorpoa
rating the new molecular findings require further refinea
ment and prospective validation, these appear to provide 
a new tool with which hematologists can identify patients 
most likely to benefit from upfront allogeneic HSCT and 
spare goodaprognosis patients from unnecessary transa
plantarelated morbidity. As the number of such genetic 
aberrations is growing and we are accumulating informaa
tion about the relative impact of each aberration on clinia
cal outcome, we propose that a scoring system incorpoa
rating all (or selected) such markers may be desirable for 
prospective decision making. There is a need to further 
explore therapeutically relevant molecular genetic lesions 
and more effective but less toxic targeted therapies for ela
derly AML patients with normal cytogenetics.
The above review provided a summary of a limited 
number of recently recognized dysregulated genes and 
their prognostic impact. More knowledge about these 
dysregulated genes and identification of additional genes 
is expected in the next few years and will be extremely 
instrumental in providing more tailored therapies for 
the heterogeneous subset of AML patients with normal 
karyotype. 
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